From overtreating good-risk patients to searching for a cure, Adam Kittai, MD, Perlmutter Cancer Center, outlines where CLL ...

Patients receiving zanubrutinib experienced a longer time to next treatment, indicating more durable disease control in routine practice.

In patients with BTK-pretreated chronic lymphocytic leukemia (CLL), AbbVie and Roche’s Venclexta (venetoclax) is the drug to ...

Researchers at the University of Eastern Finland and their international collaborators have identified key developmental and molecular differences between the two main subtypes of chronic lymphocytic ...

BeOne Medicines’ wholly owned, all-oral combination of Beqalzi (sonrotoclax) plus Brukinsa (zanubrutinib) was investigated as ...

AbbVie (NYSE:ABBV) reported positive Phase 3 results for a venetoclax-based combination in untreated chronic lymphocytic ...

New data presented at EHA 2026 showed durable long-term outcomes for BRUKINSA in patients aged 80 and older, while additional ...

Chronic lymphocytic leukemia (CLL) treatment options depend on your diagnosis. In earlier stages, “watchful waiting” may be recommended. More advanced CLL may require a combination of therapies.

Copiktra (duvelisib) is a type of cancer treatment for certain people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are slow-growing cancers that affect a ...

B-cell chronic lymphocytic leukemia (CLL) occurs when abnormal B cells accumulate in the bone marrow and blood. This crowds out healthy blood cells and weakens the body’s ability to fight infections.

Chronic lymphocytic leukemia (CLL) is a type of blood cancer in which the bone marrow makes too many lymphocytes, a type of white blood cell. CLL can affect people of any age or gender but is more ...

The alternative text for this image may have been generated using AI. Fig. 2: Olaparib induces a metabolic shift in primary CLL cells. The combination of olaparib with LDH, BTKi, or BCL2i has a ...